1. Home
  2. COGT vs RYTM Comparison

COGT vs RYTM Comparison

Compare COGT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

N/A

Current Price

$26.90

Market Cap

5.5B

Sector

Health Care

ML Signal

N/A

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$113.20

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
COGT
RYTM
Founded
2014
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.3B
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
COGT
RYTM
Price
$26.90
$113.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
19
Target Price
$55.82
★ $139.76
AVG Volume (30 Days)
★ 1.9M
1.8M
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 28.34
EPS
★ N/A
N/A
Revenue
★ $7,871,000.00
N/A
Revenue This Year
N/A
$74.20
Revenue Next Year
$5,819.52
$74.91
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.36
$74.50
52 Week High
$43.73
$122.20

Technical Indicators

Market Signals
Indicator
COGT
RYTM
Relative Strength Index (RSI) 36.08 57.34
Support Level N/A $100.33
Resistance Level $37.34 $113.31
Average True Range (ATR) 1.77 8.32
MACD -0.36 0.87
Stochastic Oscillator 6.38 78.21

Price Performance

Historical Comparison
COGT
RYTM

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: